Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1920 ARTÍCULOS , VIENDO DEL 1486 AL 1500

Use of biomarkers in the diagnosis of Alzheimer's disease in adults with intellectual disability

McFeely A, O'Connor A, Kennelly SP.

Lancet Healthy Longev. 2024 Oct;5(10):100639. doi: 10.1016/j.lanhl.2024.100639. Epub 2024 Oct 3.

Decoding paradoxical links of cytokine markers in cognition: Cross talk between physiology, inflammaging, and Alzheimer's disease- related cognitive decline

Khan H, Naseem T, Kaushik P, Narang J, Khan R, Panwar S, Parvez S.

Ageing Res Rev. 2024 Nov;101:102535. doi: 10.1016/j.arr.2024.102535. Epub 2024 Oct 6.

Clarifying the association of CSF Aβ, tau, BACE1, and neurogranin with AT(N) stages in Alzheimer disease

Lehmann S, Schraen-Maschke S, Buée L, Vidal JS, Delaby C, Hirtz C, Blanc F, Paquet C, Allinquant B, Bombois S, Gabelle A, Hanon O; Alzheimer’s Disease Neuroimaging Initiative (ADNI).

Mol Neurodegener. 2024 Oct 8;19(1):66. doi: 10.1186/s13024-024-00755-3.

Head-to-head comparison of leading blood tests for Alzheimer's disease pathology

Schindler SE, Petersen KK, Saef B, Tosun D, Shaw LM, Zetterberg H, Dage JL, Ferber K, Triana-Baltzer G, Du-Cuny L, Li Y, Coomaraswamy J, Baratta M, Mordashova Y, Saad ZS, Raunig DL, Ashton NJ, Meyers EA, Rubel CE, Rosenbaugh EG, Bannon AW, Potter WZ; Alzheimer's Disease Neuroimaging Initiative (ADNI) Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium Plasma Aβ and Phosphorylated Tau as Predictors of Amyloid and Tau Positivity in Alzheimer's Disease Project Team.

Alzheimers Dement. 2024 Nov;20(11):8074-8096. doi: 10.1002/alz.14315. Epub 2024 Oct 12.

Ocular Biomarkers in Alzheimer's Disease: Insights into Early Detection Through Eye-Based Diagnostics - A Literature Review

Firmani G, Salducci M, Testa F, Covelli GP, Sagnelli P, Lambiase A.

Clin Ter. 2024 Sep-Oct;175(5):352-361. doi: 10.7417/CT.2024.5125.

Survival time in Alzheimer's disease: An overlooked measure of safety and efficacy of disease-modifying therapies

Kurkinen M, Daly T.

Adv Clin Exp Med. 2024 Oct;33(10):1039-1043. doi: 10.17219/acem/194003.

Cognivue Clarity characterizes mild cognitive impairment and Alzheimer's disease in biomarker confirmed cohorts in the Bio-Hermes Study

Galvin JE, Kleiman MJ, Estes PW, Harris HM, Fung E.

Sci Rep. 2024 Oct 18;14(1):24519. doi: 10.1038/s41598-024-75304-5.

Timing of Alzheimer's disease biomarker progressions: A two-decade observational study from the Alzheimer's Disease Neuroimaging Initiative (ADNI)

Schaap T, Thropp P, Tosun D; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2024 Dec;20(12):9060-9067. doi: 10.1002/alz.14306. Epub 2024 Oct 21.

A meta-analysis of bulk RNA-seq datasets identifies potential biomarkers and repurposable therapeutics against Alzheimer's disease

Lamisa AB, Ahammad I, Bhattacharjee A, Hossain MU, Ishtiaque A, Chowdhury ZM, Das KC, Salimullah M, Keya CA.

Sci Rep. 2024 Oct 21;14(1):24717. doi: 10.1038/s41598-024-75431-z.

Blood-Based Biomarkers in Alzheimer's Disease: Advancing Non-Invasive Diagnostics and Prognostics

Dhauria M, Mondal R, Deb S, Shome G, Chowdhury D, Sarkar S, Benito-León J.

Int J Mol Sci. 2024 Oct 10;25(20):10911. doi: 10.3390/ijms252010911.

Comprehensive mapping of synaptic vesicle protein 2A (SV2A) in health and neurodegenerative diseases: a comparative analysis with synaptophysin and ground truth for PET-imaging interpretation

Shanaki Bavarsad M, Spina S, Oehler A, Allen IE, Suemoto CK, Leite REP, Seeley WS, Green A, Jagust W, Rabinovici GD, Grinberg LT.

Acta Neuropathol. 2024 Oct 30;148(1):58. doi: 10.1007/s00401-024-02816-9.

Epigenetic biomarkers in Alzheimer's disease: Diagnostic and prognostic relevance

Behl T, Kyada A, Roopashree R, Nathiya D, Arya R, Kumar MR, Khalid M, Gulati M, Sachdeva M, Fareed M, Patra PK, Agrawal A, Wal P, Gasmi A.

Ageing Res Rev. 2024 Dec;102:102556. doi: 10.1016/j.arr.2024.102556. Epub 2024 Oct 28.

Exploring easily accessible neurophysiological biomarkers for predicting Alzheimer's disease progression: a systematic review

Costanzo M, Cutrona C, Leodori G, Malimpensa L, D'antonio F, Conte A, Belvisi D.

Alzheimers Res Ther. 2024 Nov 4;16(1):244. doi: 10.1186/s13195-024-01607-4.

Pharmacodynamic effects of semorinemab on plasma and CSF biomarkers of Alzheimer's disease pathophysiology

Schauer SP, Toth B, Lee J, Honigberg LA, Ramakrishnan V, Jiang J, Kollmorgen G, Bayfield A, Wild N, Hoffman J, Ceniceros R, Dolton M, Bohórquez SMS, Hoogenraad CC, Wildsmith KR, Teng E, Monteiro C, Anania V, Yeh FL.

Alzheimers Dement. 2024 Dec;20(12):8855-8866. doi: 10.1002/alz.14346. Epub 2024 Nov 8.

Alzheimer's disease: part 2 - the present

Nitrini R.

Arq Neuropsiquiatr. 2024 Jun;82(6):1-9. doi: 10.1055/s-0044-1791755. Epub 2024 Nov 11.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias